The timing of insider buying — immediately following a capital-raising announcement — suggests executives see value at current levels. Traders should monitor for further insider activity and upcoming financing details, which could lead to short-term upside or dilution risk depending on terms.
Price Chart
Executive Summary
Two corporate insiders at Aprea Therapeutics — CFO John Hamill and Director Richard Peters — collectively purchased $125K of stock in open-market transactions on March 31, 2026, one day after the company announced a securities purchase agreement. The buying follows a recent pattern of insider accumulation and may signal confidence ahead of capital raising.
Key Financial Metrics
Key Facts
- CFO John Hamill purchased $25K of stock in an open-market transaction on March 31, 2026.
- Director Richard Peters purchased $100K of stock in an open-market transaction on the same day.
- Total open-market purchases in the cluster amount to $125K, representing ~1.4% of the company's $9M market cap.
- The purchases occurred one day after the company filed an 8-K disclosing a securities purchase agreement for an undisclosed amount.
- Non-cash transactions (grants/withholding) were also reported but do not contribute to economic signal.
Financial Impact
$125,000 in open-market buying by two insiders, or 1.4% of market cap
Risk Factors
- The concurrent securities purchase agreement may lead to share dilution, potentially offsetting positive sentiment from insider buying.
- Small market cap makes the stock vulnerable to volatility and low liquidity.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CLUSTER Data (Synthetic) | cluster-APRE-1775074600727 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 28, 2026 8w ago | 8-K | $0.8386 | awaiting T+60 | — | $0.5180 (−38.23%) |
Aug 12, 2026 10w ago | 8-K | $0.6830 | awaiting T+60 | — | $0.5180 (−24.16%) |
Aug 12, 2026 10w ago | Press Release | $0.6830 | awaiting T+60 | — | $0.5180 (−24.16%) |
May 13, 2026 23w ago | 8-K | $0.8800 $0.6503 | ▼ −26.10% | ▼ −30.54% | $0.5180 (−41.14%) |
May 13, 2026 23w ago | Press Release | $0.8800 $0.6503 | ▼ −26.10% | ▼ −30.54% | $0.5180 (−41.14%) |
Apr 30, 2026 25w ago | DEFA14A | $0.8000 $0.6247 | ▲ +21.91% | ▲ +25.02% | $0.5180 (+35.25%) |
Apr 22, 2026 26w ago | S-3 | $0.8840 $0.6690 | ▲ +24.32% | ▲ +29.34% | $0.5180 (+41.40%) |
Apr 21, 2026 26w ago | Press Release | $0.9070 $0.6900 | ▼ −23.93% | ▼ −30.82% | $0.5180 (−42.89%) |
Mar 31, 2026 29w ago | Insider Cluster | $0.7630 $0.7900 | ▲ +3.54% | ▼ −8.84% | $0.5180 (−32.11%) |
Mar 20, 2026 31w ago | EFFECT | $0.7620 $0.6990 | ▼ −8.27% | ▼ −22.69% | $0.5180 (−32.02%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers